


Updates of colorectal cancer liver metastases therapy: review on DEBIRI

Giammaria Fiorentini^{*,1} , Donatella Sarti¹, Roberto Nani², Camillo Aliberti³, Caterina Fiorentini⁴ & Stefano Guadagni⁵

¹Onco-Hematology Department, Azienda Ospedaliera 'Ospedali Riuniti Marche Nord', 61122 Pesaro, Italy

²Department of Radiology, University Milano Bicocca, ASST Papa Giovanni XXIII, Piazza OMS - Organizzazione Mondiale della Sanità 1, 24127 Bergamo, Italy

³Oncology Radiodiagnosics Department, Oncology Institute of Veneto, Institute for the Research & Treatment of Cancer, 35128 Padova, Italy

⁴Department of Medical Biotechnologies, Division of Cardiology, University of Siena, 53100 Siena, Italy

⁵Department of Applied Clinical Sciences & Biotechnology, Section of General Surgery, University of L'Aquila, via Vetoio 67100 L'Aquila, Italy

*Author for correspondence: Tel.: +39 0721 364124; Fax: +39 0721 364094; g.fiorentini@alice.it

Hepatic Oncology

Colorectal cancer is a worldwide public health issue, presenting an advanced stage at diagnosis in more than 20% of patients. Liver metastases are the most common metastatic sites and are not indicated for resection in 80% of cases. Unresectable colorectal cancer liver metastases that are refractory to systemic chemotherapy may benefit from transarterial chemoembolization with irinotecan-loaded beads (DEBIRI). Several studies show the safety and efficacy of DEBIRI for the treatment of colorectal cancer liver metastases. The development of transarterial chemoembolization and the introduction of new embolics have contributed to better outcomes of DEBIRI. This article reviews the current literature on DEBIRI reporting its use, efficacy in terms of tumor response and survival and side effects.

First draft submitted: 19 September 2019; Accepted for publication: 19 December 2019; Published online: 21 January 2020

Keywords: colorectal cancer • CRC-LM • DEBIRI • liver metastases • liver resection

DEBIRI for colorectal cancer liver metastases treatment

Despite the introduction of new chemotherapeutic agents and the development of locoregional therapies (embolization, percutaneous ablation, hepatic arterial-directed infusion chemotherapy, internal radiation) that have contributed to better outcomes for colorectal cancer liver metastases (CRC-LM) [1,2], there is still a lack of standardized evidence-based protocols for optimal CRC-LM management [3].

Conventional transarterial chemoembolization (cTACE) with lipiodol has positive results for the treatment of hepatocellular carcinoma (HCC) [4] and for CRC-LM when used in combination therapies. Clinical indications for DEBIRI according to European Society for Medical Oncology and National Comprehensive Cancer Network [1] are: presence of advanced disease that is not indicated to surgery and/or refractory to systemic therapy, Eastern Cooperative Oncology Group 2, Child-Pugh B, Barcelona Clinic Liver Cancer C, normal hematological values, ALT and GGT $<3 \times$ upper limit of normal levels; total bilirubin <2.5 mg/m. [5–8]. This indication is confirmed by several studies and recent reviews [1,2,7,8]. European Society for Medical Oncology

The comparison of hepatic arterial therapies (radioembolization and TACE) in CRC-LM patients shows a similar median overall survival (OS) of 15.2 months [6], suggesting their positive efficacy in these patients. More recently, there has been an increasing use of TACE with irinotecan-loaded drug eluting beads (DEBIRI) in the treatment of CRC-LM [7–9]. This article reviews the current literature on DEBIRI reporting its use, efficacy in terms of tumor response and survival and side effects.

DEBIRI: mechanism & function

The use of drug eluting beads (DC-Beads) for the intra-arterial delivery of irinotecan was introduced in early 20th century for the treatment of CRC-LM [10–17]. DEBIRI involves the delivery of DC-Beads inside the hepatic artery

of the lobe mainly affected by tumor metastases. TACE is also used in patients with bilobar disease, alternating the lobe in individual treatments. The tumor specificity of DEBIRI is given by the presence of a richer vascularity inside the tumor than in the normal liver tissue [18]. DEBIRI efficacy has been confirmed by several studies showing high percentage of tumor response [10–17].

DEBIRI selectivity, however, is different from that of TACE with doxorubicin in HCC. This may be due to the different loco regional activity of irinotecan and the necrotic activity of doxorubicin [19]. The irinotecan is rapidly released from DC-Beads inside tumor metastases, reducing significantly the systemic exposure to the drug and increasing its local concentration. DC-Beads, moreover, occlude liver arterial vessels, increasing the selectivity for tumor tissue that is supplied mainly by hepatic arterial circulation. The normal liver tissue, on the contrary, is mainly supplied by the portal vein and is not affected by the ischemia induced by TACE, as shown in animal models [20]. The ischemic effect alone is not enough to justify the extent of tumor response observed but also the irinotecan effect is required. The use of DC-Beads alone, indeed, results in a lower tumor response than that observed in a dose-dependent manner of DEBIRI, confirming the importance of both embolization and drug activity [21]. Another important result of embolization-induced ischemia is the rapid decrease of liver pH that activate irinotecan [22].

DEBIRI activity & clinical application

Type & size of the embolics

There are several types of embolics for the irinotecan delivery. Recent improvements of TACE, including the introduction of new types of embolics (PEG microspheres), have increased tumor response in CRC-LM patients [23,24]. Some type of beads (LUMI) incorporate an imaging agent and can be loaded with a chemotherapeutic drug and can be visualized during TACE and in follow-up imaging [25–27].

The available beads diameters are different and can be selected according to tumor size and vascularization. At first, the DC-Beads of 100–300 μm were the most used [16], later the 70–150 μm DC-Beads M1 were introduced [28] because of the hypo vascularity of CRC-LM. The smaller diameter allowed a more distal penetration of the beads [29], allowing a higher concentration of irinotecan administered inside the tumor and fewer adverse events [30]. A comparison between DEBIRI performed using DC-Beads with small (70–150 μm) versus big (100–300 μm) diameter showed that small beads delivered significantly ($p > 0.005$) a higher drug concentration (96%) inside the target than the big beads (79%) and a complete stasis in a lower number of TACE in CRC-LM patients ($p < 0.005$) [31,32]. This result was further supported by the pharmacokinetic study of irinotecan release from small and big size DC-Beads that showed an advantage for small size beads as concerning the maximum concentration of irinotecan observed in the target area and low adverse events [33]. This effect may be due to a higher surface area/volume associated with DC-Beads M1. However, the 100–300 μm beads remain the most used size (Table 1).

The DC-Beads 40 μm diameter embolic microspheres were recently introduced for DEBIRI, resulting in small toxicity and good efficacy: local tumor control of 88.9%, median liver progression-free survival (PFS) of 5.9 months and median OS of 13.5 months [38].

DC-Beads are loaded with irinotecan. Irinotecan molecule terminates in an open-ring carboxylate that is converted to a closed-ring lactone (active form) in a pH-dependent manner [21]. This latter form binds better to the sulfonate groups that are present in the DC-Beads [21]. Irinotecan is loaded to the beads in a prodrug form and is activated by carboxylesterase that are present in several parts of the body, such as gut, liver and blood [21]. The activated drug can bind to its target (TOPO-1) 1000-times stronger than the inactive form and interferes with DNA replication, resulting in single strand breaks in DNA and hence, apoptosis of the tumor cell [21].

DEBIRI-related side effects

Due to the local delivery of irinotecan, DEBIRI does not induce dose-dependent side effects (neutropenia and diarrhoea) that are generally observed as a consequence of the systemic administration [13–16]. The adverse events commonly observed after TACE are fever without associated sepsis, pain in the right upper quadrant, pain due to capsular stretching associated with postinterventional reaction and swelling, nausea and/or vomiting (Table 1) [39]. These symptoms are referred to as postembolization syndrome. Right upper quadrant pain is the most discomforting adverse event, in particular during the beads injection. Incidence of adverse events correlated to DEBIRI varies between different studies, median incidence is 57% for nonserious adverse event and 11% for serious adverse events (Tables 2 & 3).

Table 1. DEBIRI support therapy protocols and adverse events in colorectal cancer liver metastases.

Study (year)	Patients (n)	Intra-arterial support therapy	Embolic type	Embolic diameter (μm)	Average irinotecan dosage (mg)	Type of adverse event	Peri-procedural therapy	Ref.
Fiorentini <i>et al.</i> (2017)	50	Lidocaine	LP	100	200	Pain 16 (32%) Fever 7 (14%) Hypertransaminasemia 10 (20%)	Intravenous hydration 10 mg morphine 2 mg ondasetron 400 mg Ciprofloxacin Paracetamol in the case of fever	[23]
Ranieri <i>et al.</i> (2016)	25	No	HS	100–300	100–200	Pain 22% Hypertension 30% Fever 16% Hypertransaminasemia 69%	Intravenous hydration Morphine Antiemetic and antibiotic prophylaxis Morphine post-procedure	[34]
Stutz <i>et al.</i> (2015)	27	No	DC	100–300, 300–500	50–200	Nausea 8 (30%) Vomiting 6 (22%) Right upper quadrant Pain 5(59%) Fatigue 9 (33%) Ascites 6 (22%)	Antiemetics Antibiotics and standards protocol for right upper quadrant pain prevention	[35]
Fiorentini <i>et al.</i> (2015)	40	Lidocaine	DC	100–300, 300–500	200	PES 20 (30%) Gastritis 6 (15%) Dehydration (G2) 2 (5%) Cholecystitis (G3) 1 (2.5%) Hypertension (G2) 7 (17.5%)	Intravenous hydration 10 mg morphine 2 mg ondasetron 400 mg Ciprofloxacin Paracetamol in case of fever	[36]
Eichler <i>et al.</i> (2012)	25	Lidocaine	DC	100–300, 300–500	73	Nausea 8 (30%) Vomiting 6 (22%) Right upper quadrant Pain 17 (59%) Fatigue 9 (33%) Ascites 6 (22%)	Pethidine Granisetron	[37]
Fiorentini <i>et al.</i> (2012)	36	Lidocaine	DC	100–300, 300–500	200	Pain 30% Vomiting 25% Diarrhea 2% Asthenia 20% Leukopenia 5% Anaemia 5% Fever 15% Alopecia 5%	Intravenous hydration 10 mg morphine 2 mg ondasetron 400 mg Ciprofloxacin Paracetamol in case of fever	[16]

DC: Drug eluting bead (Biocompatibles, Farnham, UK); HS: HepaSphere (BioSphere Medical, Roissy-en-France, France); LP: LifePearl (Terumo, Leuven, Belgium); ND: Not declared; PES: Postembolic syndrome.

There are different opinions concerning the origin of this type of pain. At first it was deemed the irinotecan responsible for pain, however, the systemic infusion of irinotecan does not cause pain [12]. Another hypothesis is that the swelling induced by the osmotic alteration correlated to the loading solution of the beads, however, intrahepatic infusion of irinotecan at high concentration does not cause pain [10–12,14].

In some cases, the origin of pain may be due to the mislocalization of the beads that are not delivered inside the target but reach extra target tissues such as the cholecystitis as the result of patients' arterial vessel anomalies [39]. The introduction of radiopaque DC Beads LUMI™ allows to rapidly detect the mislocalization and to prevent the correlated adverse event.

Notwithstanding the unclear origin of pain, it can be prevented with supportive therapy with morphine and intra-arterial lidocaine that are administered before the TACE, and antibiotic/antiemetic prophylaxis and intravenous hydration before and after the procedure [39].

In the past decade, several efforts have been made to improve TACE tolerability, including drug dosage adjustments, incremental experience of interventional radiologist, introduction of new type of drugs and microspheres to obtain a more precise and selective treatment [23–27].

Support therapy protocol for DEBIRI

From 2006, Fiorentini and colleagues developed a pre- and post-procedural supportive therapy to prevent and limit acute toxic effects correlated to the DEBIRI procedure. This protocol includes a careful therapy with morphine and intra-arterial lidocaine that are administered before the DEBIRI, and antibiotic/antiemetic prophylaxis and

Table 2. DEBIRI results in prospective single arm studies.

Study	Aims	Prior CHT	Patients (n)	OS	PFS	AE	SAE	Ref.
Aliberti <i>et al.</i> (2011)	Safety	Yes	82	25 months	TTP 8 months	N/A	25%	[40]
Martin <i>et al.</i> (2011)	Safety efficacy	Yes	55	19 months	11 months	28 in 99 sessions	7 in 99 sessions	[41]
Eichler <i>et al.</i> (2012)	Safety	Yes	11	N/A	TTP 5.1 months	43 in 9 sessions	None	[37]
Martin <i>et al.</i> (2012)	Safety	No	10	N/A	N/A	99 in 10 PTS	4 in 40 PTS	[42]
Iezzi <i>et al.</i> (2015)	Safety efficacy	Yes	20	7.3 months	4 months	64 in 54 sessions	2 in 54 sessions	[43]
Pellerin <i>et al.</i> (2019)	Efficacy	No	57	33 months	10.8 months	G2 10–25%	G3–4 5–9%	[44]
Martin <i>et al.</i> (2015)	Safety efficacy	Yes	30	N/A	N/A	19 in 57 sessions	3 in 57 sessions	[42]
Bhutiani <i>et al.</i> (2016)	Safety efficacy	Yes	296	88% at 12 months	N/A	105 in 666 sessions	30 in 666 sessions	[45]
Akinwande <i>et al.</i> (2016)	Safety efficacy 70–150 μ m	Yes	15	13 months	N/A	2 in 32 sessions	None	[32]
Scevola <i>et al.</i> (2017)	Safety efficacy	Yes	62	27,5% at 51 months	N/A	79 in 174 sessions	None	[46]

AE: Adverse event; CHT: Chemotherapy; G: Grade; IRI: Irinotecan; N/A: Not applicable; OS: Overall survival; PFS: Progression-free survival; PTS: Patient; SAE: Serious adverse event; TTP: Time to progression.

Table 3. DEBIRI results in randomized controlled studies.

Study	Aims	Prior CHT	Patients (n)	OS	PFS	AE G1–2	SAE G3–4	Ref.
Fiorentini <i>et al.</i> (2012)	DEBIRI vs FOLFIRI	Yes	74	22 vs 15 months ($p = 0.031$)	7 vs 4 months ($p = 0.006$)	14 vs 18%	2 vs 4%	[16]
Martin <i>et al.</i> (2015)	FOLFOX+/- Beva + DEBIRI vs FOLFOX+/- Beva	No	70	Not reached at publication time	15 vs 12 months ($p > 0.05$)	973 vs 459	57 vs 15	[42]
Fiorentini <i>et al.</i> (2019)	DEBIRI vs DEBIRI + BEVA	Yes	30	5.8 vs 12 months	4 vs 6 months	12 vs 16	None	[47]

AE: Adverse event; BEVA: Bevacizumab; CHT: Chemotherapy; G: Grade; OS: Overall survival; PFS: Progression-free survival; SAE: Serious adverse event.

intravenous hydration before and after the procedure. This protocol allows a tolerability of 90% [13–16,23,24]. The cardiac evaluation with echocardiography did not reveal any significant variation before and after last TACE [23,24]. Hence DEBIRI could be considered safe as concerning the cardiac profile, unless in presence of concomitant heart disease.

The analysis of the literature shows that only few studies detail the protocol of supportive therapy for patients that undergo TACE [34–37,48–50]. Ranieri and colleagues, for example, administer intravenous hydration, antiemetic and antibiotic prophylaxis, and morphine to reduce post embolic syndrome. Morphine is also administered in the postprocedure period [34].

All patients were treated according to hospital procedure for TACE; routine prophylactic treatments against nausea and vomiting, infection and upper right quadrant pain were also given to patients prior to the procedure. These included antiemetic medications as well as antibiotics and were given prior to TACE procedures (Table 3) [35].

General recommendations to avoid pain are: to explain the procedure very well to the patient and their family; to create a welcoming and calm environment in the IR room; to adopt periprocedural medications and lidocaine IA; to perform Lobar Infusion, to avoid the complete flow block; to perform a slow infusion for 1 min for 1 ml of solution; to shake the syringe to keep the beads in suspension; to stop and restart the TACE if pain appears, without hurry; not to perform control angiogram because this causes beads to move out of the target; to carefully monitor the patient after TACE.

Radiological assessment & tumor response evaluation after DEBIRI in CRC-LM

The radiological study of CRC-LM is required for the assessment of tumor response and can be done using MRI, computed tomography (CT) and positron emission tomography (PET) scan [51]. Specificity for the detection of

Table 4. DEBIRI results in single arm studies: tumor responses.

Study	Patients (n)	Responders (CR+PR) mRECIST (%)	PFS (months)	OS (months)	Ref.
Aliberti <i>et al.</i> (2011)	82	78	8	25	[40]
Akinwande <i>et al.</i> (2014)	149	40	7	13	[69]
Bhutiani <i>et al.</i> (2016)	212	53	NR	NR	[45]
Eichler <i>et al.</i> (2012)	11	22	5	NR	[37]
Fiorentini <i>et al.</i> (2015)	40	50	9.8	20.4	[36]
Huppert <i>et al.</i> (2014)	29	72 (EASL)	5	8	[70]
Iezzi <i>et al.</i> (2015)	20	10	4	7.3	[43]
Martin <i>et al.</i> (2011)	55	65	11	19	[41]
Nayaranan <i>et al.</i> (2013)	28	45	4	13.3	[71]
Fereydooni <i>et al.</i> (2018)	14	69.23	NR	18.14	[33]
Pellerin <i>et al.</i> (2019)	57	73.2	10.8	33.1	[44]

CR: Complete response; EASL: European Association for the Study of the Liver; OS: Overall survival; PFS: Progression-free survival; PR: Partial response.

liver metastases of CT, MRI and PET is very high: 95, 93, 97%, respectively [52]. CT scans, however, are not always adequate as radiological tool to assess tumor response of DEBIRI [53]. MRI with liver-specific contrast agents has a higher sensitivity, especially when underlying liver diseases (steatosis, cirrhosis) are present or for the identification of very small lesions (<1 cm), and for this reason it is better than CT [54]. PET scan allows to obtain whole body map and a recent study shows that it is the best radiological method for the assessment of liver metastases from gastrointestinal tumors, even if it can have high false negative rates in patients recently treated with chemotherapy [55,56]. PET scan can be associated to CT scan thus improving the sensitivity up to 97% [52].

Tumor response evaluation is very important in patients with liver tumor that are treated with DEBIRI. The Tumor response–Response Evaluation Criteria in Solid Tumors (RECIST) and WHO has been used since early nineties for tumor response evaluation in clinical trials [57–60]. The European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of cancer has formulated Clinical Practice Guidelines. These guidelines establish that tumor assessment should be done using Modified Tumor response–Response Evaluation Criteria in Solid Tumors (mRECIST) to assess CT or MRI done 4 weeks after treatment. Conventional RECIST criteria are based on tumor shrinkage to measure tumor response. TACE and TARE, however, induce tumor damage and for this reason, there can be tumor response even if the tumor size is the same. The reduction in viable tumor is a better way to estimate tumor response in these cases and for this reason, RECIST criteria was modified [59].

The mRECIST has been recently introduced to overcome the limitations of RECIST and now it is the most used method to assess tumor response in CRC-LM after DEBIRI treatment [34,35,48,49]. This method assesses tumor response as identification of intratumoral necrotic areas and reduction of tumor burden in triphasic CT or MRI [61]. Other modifications of the RECIST include monitoring of vascular invasion, lymph nodes, ascites, pleural effusion and presence of new lesions [62,63].

DEBIRI in combination therapies

DEBIRI can be associated to systemic therapies to target extrahepatic diseases. The combination of DEBIRI with chemotherapy based on FOLFOX with or without bevacizumab has limited toxicity and higher overall response [64,65]. The combination DEBIRI-FOLFOX or FOLFIRI is also successful for unresectable CRC-LM therapy [66,67]. DEBIRI in association with capecitabine can be used in heavily pretreated patients with positive tolerability and tumor response rates [68]. Also the combination DEBIRI + Cetuximab is safe and active [36].

DEBIRI efficacy

Cumulative results from single arm studies [40–46,69–72] on DEBIRI show that the median OS is 18 months (range 7.3–25) and 33 months when DEBIRI is combined to FOLFOX 6 (Table 4). Median PFS is 6.7 months (range 4–11) and 10.8 months when DEBIRI is combined to FOLFOX 6 (Table 4). As concerning the tumor response, median overall response rate was 62% (range 10–78%; Tables 2–4).

Other studies, according to the method used for tumor response evaluation (RECIST vs mRECIST/EASL), report an objective tumor response ranging between 56.2 and 51.1% [7–9]. These data further support the beneficial effect of DEBIRI for the treatment of CRC-LM.

Predictive factors

Survival according to clinical and molecular characteristics of patients can be correlated to CEA level and it could be used as biomolecular prognostic marker in CRC-LM patients treated with DEBIRI [68]. A study monitoring CEA and CA19.9 levels in CRC-LM patients after DEBIRI find an interesting correlation between longer survival and significant CEA level reduction ($\geq 20\%$), however, the correlation between CEA reduction and tumor response was not statistically significant [68]. If these data are confirmed by further studies with a larger number of patients, DEBIRI could be interrupted in case of CEA levels stability after the first treatment, in order to avoid further sessions that could be not effective.

Another potential biomarker for predicting treatment efficacy and risk of adverse events after DEBIRI is VEGFR1. A recent study monitored the VEGF/R1/R2 levels in colorectal cancer patients after TACE treatment [33]. They showed a decreased VEGFR1 level, but not VEGF and VEGFR2 at 24 h post-treatment. This downregulation of VEGFR1 is associated with the antitumor effect of VEGF and may be correlated with better prognosis [33]. The potential prognostic value of VEGFR1, however, is not confirmed in a conclusive manner, further studies are required to address this issue.

Conclusion

DEBIRI is a promising intra-arterial approach that can be offered alone or in combination with systemic chemotherapy after failure of previous chemotherapy lines. cTACE with lipiodol has positive results for the treatment of HCC [4] and for CRC-LM when used in combination therapies [72]. One recent study on the palliative and neoadjuvant use (with subsequent thermal ablation) of cTACE in unresectable and chemoresistant CRC-LM reports a median OS and PFS of 12.6 and 5.9 months in the palliative setting and 25.8 and 10.8 months for the neoadjuvant use of cTACE [72]. This suggest that cTACE is a more effective treatment option in advanced nonresectable CRC-LM if associated to thermal ablation or other chemotherapeutics (MitomycinC, irinotecan) [72]. TACE can be used in both palliative and therapeutic settings.

DEBIRI is safe and effective for the treatment of unresectable CRC-LM. Irinotecan is a pro-drug and requires activation, occurring in normal liver parenchyma, for this reason lobar infusions should to be preferred. The pH-dependent nature of irinotecan activation and the DEBIRI-induced tumor hypoxia is a unique mechanism of treatment. Periprocedural medications are available to control pain and do not reduce responses to DEBIRI.

Further randomized trials to determinate the ideal patient population, the best timing of treatment, the best techniques for beads delivery are warranted.

Future perspective

Patients with liver metastases from colorectal cancer are often unresectable and/or refractory to systemic therapy, for this reason they are indicated for locoregional therapy. DEBIRI is among the most used locoregional method and is safe and effective for the treatment of unresectable CRC-LM. DEBIRI can also be used as macro-antiangiogenic therapy. This effect can be further enhanced by the combination of DEBIRI with molecular antiangiogenic therapy, such as of bevacizumab, in order to reduce neo-angiogenesis embolization-induced. This could reduce also recurrences while increasing PFS and survival, optimizing the patient's care.

Financial & competing interests disclosure

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Open access

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Executive summary

- DEBIRI involves the delivery of DC-Beads inside the hepatic artery of the lobe mainly affected by tumor metastases.
- The tumor specificity of DEBIRI is given by the presence of a richer vascularity inside the tumor than in the normal liver tissue.
- DEBIRI efficacy has been confirmed by several studies showing high percentage of tumor response and improved overall survival.
- There are several types of embolics for the irinotecan delivery. Recent improvements of transarterial chemoembolization (TACE), including the introduction of new types of embolics (PEG microspheres), have increased tumor response in colorectal cancer liver metastases patients.
- The adverse events commonly observed after TACE are fever without associated sepsis, pain in the right upper quadrant, pain due to capsular stretching associated with postinterventional reaction and swelling, nausea and/or vomiting.
- Supportive therapy protocol includes a careful therapy with morphine and intra-arterial lidocaine that are administered before the TACE, and antibiotic/antiemetic prophylaxis and intravenous hydration before and after the procedure.
- The Modified Tumor response–Response Evaluation Criteria in Solid Tumors (mRECIST) has been recently introduced to overcome the limitations of RECITS and now it is the most used method to assess tumor response in colorectal cancer liver metastases after DEBIRI treatment.
- The combination DEBIRI with FOLFOX, FOLFIRI or Cetuximab is successful for unresectable colorectal cancer liver metastases therapy and safe.

References

Papers of special note have been highlighted as: • of interest •• of considerable interest

1. Gruber-Rouh T, Marko C, Thalhammer A *et al.* Current strategies in interventional oncology of colorectal liver metastases. *Br. J. Radiol.* 89(1064), 20151060 (2016).
2. Jones RP, Malik HZ, Fenwick SW *et al.* PARAGON II – a single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. *Eur. J. Surg. Oncol.* 42(12), 1866–1872 (2016).
- **First study of DEBIRI as neoadjuvant therapy.**
3. Levy J, Zuckerman J, Garfinkle R *et al.* Intra-arterial therapies for unresectable and chemorefractory colorectal cancer liver metastases: a systematic review and meta-analysis. *HPB (Oxford)* 20(10), 905–915 (2018).
4. Lo CM, Ngan H, Tso WK *et al.* Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 35(5), 1164–1171 (2002).
5. Lammer J, Malagari K, Vogl T *et al.* Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc. Intervent. Radiol.* 33(1), 41–52 (2010).
6. Zacharias AJ, Jayakrishnan TT, Rajeev R *et al.* Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases: a meta-analysis. *PLoS ONE* 10(10), e0139940 (2015).
- **Major metanalysis of hepatic artery therapies.**
7. Akinwande O, Dendy M, Ludwig JM, Kim HS. Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: a systematic review. *Surg. Oncol.* 26(3), 268–275 (2017).
- **Most important systematic review on DEBIRI.**
8. Liu DM, Thakor AS, Baerlocher M *et al.* A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof. *Future Oncol.* 11(9), 1421–1428 (2015).
- **Interesting review on conventional chemoembolization.**
9. Young S, D'Souza D, Flanagan S, Golzarian J. Review of the clinical evidence for the use of DEBIRI in the treatment of colorectal metastatic disease. *Cardiovasc. Intervent. Radiol.* 40(4), 496–501 (2017).
10. Fiorentini G, Poddie DB, Cantore M *et al.* Locoregional therapy for liver metastases from colorectal cancer: the possibilities of intraarterial chemotherapy, and new hepatic-directed modalities. *Hepatogastroenterology* 48(38), 305–312 (2001).
11. Fiorentini G, Rossi S, Bernardeschi P, Cantore M, Guadagni S. Is there a new drug beyond floxuridine for intra-arterial hepatic chemotherapy in liver metastases from colorectal cancer? *J. Clin. Oncol.* 23(9), 2105 (2005).
12. Fiorentini G, Rossi S, Dentico P *et al.* Irinotecan hepatic arterial infusion chemotherapy for hepatic metastases from colorectal cancer: a Phase II clinical study. *Tumori* 89(4), 382–384 (2003).
13. Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. *Anticancer Res.* 26(5B), 3793–3795 (2006).

14. Fiorentini G, Aliberti C, Turrisi G *et al.* Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a Phase II clinical study. *In Vivo* 21(6), 1085–1091 (2007).
15. Fiorentini G, Aliberti C, Benea G *et al.* TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. *Hepatogastroenterology* 55(88), 2077–2082 (2008).
16. Fiorentini G, Aliberti C, Tilli M *et al.* Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a Phase III study. *Anticancer Res.* 32(4), 1387–1395 (2012).
- **First randomized clinical trial on DEBIRI.**
17. Martin RC, Joshi J, Robbins K, Tomalty D, O'Hara R, Tatum C. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. *J. Oncol.* 2009, 539795 (2009).
18. Lencioni R, Aliberti C, De Baere T *et al.* Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. *J. Vasc. Intervent. Radiol.* 25(3), 365–369 (2014).
- **Significant technical recommendations for DEBIRI.**
19. Lencioni R, Baere T, Burrel M *et al.* Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. *Cardiovasc. Intervent. Radiol.* 35(5), 980–985 (2012).
20. Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL. Irinotecan drug eluting beads for use in chemoembolization: *in vitro* and *in vivo* evaluation of drug release properties. *Eur. J. Pharm. Sci.* 30(1), 7–14 (2007).
- **First pharmacological study on irinotecan drug-eluting beads.**
21. Lewis AL, Hall B. Toward a better understanding of the mechanism of action for intra-arterial delivery of irinotecan from DC Bead (DEBIRI). *Future Oncol.* 15(17), 2053–2068 (2019).
22. Brooks AJ, Hammond JS, Girling K, Beckingham IJ. The effect of hepatic vascular inflow occlusion on liver tissue pH, carbon dioxide, and oxygen partial pressures: defining the optimal clamp/release regime for intermittent portal clamping. *J. Surg. Res.* 141(2), 247–251 (2007).
23. Fiorentini G, Carandina R, Sarti D *et al.* Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer. *World J. Gastroint. Oncol.* 9(9), 379–384 (2017).
24. Aliberti C, Carandina R, Sarti D *et al.* Hepatic arterial infusion of polyethylene glycol drug-eluting beads for primary and metastatic liver cancer therapy. *Anticancer Res.* 36(7), 3515–3521 (2016).
25. Dreher MR, Sharma KV, Woods DL *et al.* Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. *J. Vasc. Interv. Radiol.* 23(2), 257–264 (2012).
26. Kilcup N, Tonkopi E, Abraham RJ, Boyd D, Kehoe S. Composition-property relationships for radiopaque composite materials: pre-loaded drug-eluting beads for transarterial chemoembolization. *J. Biomater Appl.* 30(1), 93–103 (2015).
27. Sharma KV, Dreher MR, Tang Y *et al.* Development of “imageable” beads for transcatheter embolotherapy. *J. Vasc. Interv. Radiol.* 21(6), 865–876 (2010).
28. Lewis AL, Dreher MR, O'Byrne V *et al.* DC BeadM1TM: towards an optimal transcatheter hepatic tumor therapy. *J. Mater. Sci. Mater. Med.* 27(1), 1–12 (2016).
29. Dreher MR, Sharma KV, Woods DL *et al.* Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. *J. Vasc. Interv. Radiol.* 23(2), 257–264 (2012).
30. Odisio BC, Ashton A, Yan Y *et al.* Transarterial hepatic chemoembolization with 70–150 μm drug-eluting beads: assessment of clinical safety and liver toxicity profile. *J. Vasc. Interv. Radiol.* 26(7), 965–971 (2015).
31. Akinwande OK, Philips P, Duras P, Pluntke S, Scoggins C, Martin RC. Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: a propensity score matching analysis. *Cardiovasc. Intervent. Radiol.* 38(2), 361–371 (2015).
32. Akinwande O, Scoggins C, Martin RC. Early experience with 70–150 μm irinotecan drug-eluting beads (M1-DEBIRI) for the treatment of unresectable hepatic colorectal metastases. *Anticancer Res.* 36(7), 3413–3418 (2016).
33. Fereydooni A, Letzen B, Ghani MA *et al.* Irinotecan-eluting 75–150- μm embolics lobar chemoembolization in patients with colorectal cancer liver metastases: a prospective single-center Phase I study. *J. Vasc. Interv. Radiol.* 29(12), 1646–1653.e5 (2018).
34. Ranieri G, Niccoli A, Altini C *et al.* A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience. *Onco. Targets Ther.* 9, 7527–7535 (2016).
35. Stutz M, Mamo A, Valenti D *et al.* Real-life report on chemoembolization using DEBIRI for liver metastases from colorectal cancer. *Gastroenterol. Res. Pract.* 2015, 715102 (2015).
36. Fiorentini G, Aliberti C, Sarti D *et al.* Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. *World J. Gastrointest. Oncol.* 7(6), 47–54 (2015).
- **One of the first locoregional therapy associated to systemic cetuximab.**

37. Eichler K, Zangos S, Mack MG *et al*. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). *Int. J. Oncol.* 41(4), 1213–1220 (2012).
38. Mauri G, Varano GM, Della Vigna P *et al*. Transarterial embolization with small-Size particles loaded with irinotecan for the treatment of colorectal liver metastases: results of the MIRACLE III Study. *Cardiovasc. Intervent. Radiol.* 41(11), 1708–1715 (2018).
39. Aliberti C, Carandina R, Sarti D *et al*. Transarterial chemoembolization with DC Bead LUMI™ radiopaque beads for primary liver cancer treatment: preliminary experience. *Future Oncol.* 13(25), 2243–2252 (2107).
40. Aliberti C, Fiorentini G, Muzzio PC *et al*. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead(R), drug-eluting bead loaded with irinotecan: results of a phase II clinical study. *Anticancer Res.* 31(12), 4581–4587 (2011).
41. Martin RC, Joshi J, Robbins K *et al*. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. *Ann. Surg. Oncol.* 18(1), 192–198 (2011).
42. Martin RC, Scoggins CR, Schreeder M *et al*. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. *Cancer* 121(20), 3649–3658 (2015).
43. Iezzi R, Marsico VA, Guerra A *et al*. Trans-arterial chemoembolization with irinotecan-loaded drug-eluting beads (DEBIRI) and capecitabine in refractory liver prevalent colorectal metastases: a phase II single-Center study. *Card. Interventional Radiol.* 38(6), 1523–1531 (2015).
44. Pellerin O, Pernet S, Vidal V, Taieb J, Moussa N, Sapoval M. Irinotecan drug-eluting beads chemoembolization (DEBIRI) plus mFolfox6 as front-line treatment in patients with non resectable liver dominant metastases of colorectal cancer (FFCD 1201 phaseII trial): result of single-arm, open-label Phase II study. *JVIR S29* (2019). [www.jvir.org/article/S1051-0443\(18\)31946-8/pdf](http://www.jvir.org/article/S1051-0443(18)31946-8/pdf)
45. Bhutiani N, Akinwande O, Martin RCG. Efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases. *World J. Surg.* 40(5), 1178–1190 (2016).
46. Scevola G, Loreni G, Rastelli M, Sposato S, Ramponi S, Miele V. Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization. *Med. Oncol.* 34(3), 37 (2017).
47. Fiorentini G, Sarti D, Nardella M *et al*. Chemoembolization alone or associated to bevacizumab for the therapy of colorectal cancer metastases (CRC): preliminary results of a randomized study. *In vivo*. In Press.
48. Schicho A, Hellerbrand C, Krüger K *et al*. Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) levels. *J. Clin. Transl. Hepatol.* 4(4), 288–292 (2016).
49. Hartnell GG, Gates J, Stuart K, Underhill J, Brophy DP. Hepatic chemoembolization: effect of intraarterial lidocaine on pain and postprocedure recovery. *Cardiovasc. Intervent. Radiol.* 22(4), 293–297 (1999).
50. Fiorentini G, Aliberti C, Mulazzani L *et al*. Chemoembolization in colorectal liver metastases: the rebirth. *Anticancer Res.* 34(2), 575–584 (2014).
51. Glover C, Douse P, Kane P *et al*. Accuracy of investigations for asymptomatic colorectal liver metastases. *Dis. Colon. Rectum* 45(4), 476–484 (2002).
52. Nielke MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR Imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. *Radiology* 257(3), 674–684 (2010).
53. Jones RP, Stattner S, Dunne DF *et al*. Radiological assessment of response to neoadjuvant transcatheter hepatic therapy with irinotecan-eluting beads (DEBIRI) for colorectal liver metastases does not predict tumor destruction or long-term outcome. *Eur. J. Surg. Onc.* 39(10), 1122–1128 (2013).
54. Choi DJ, Kwak JM, Kim J, Woo SU, Kim SH. Preoperative chest computerized tomography in patients with locally advanced mid or lower rectal cancer: its role in staging and impact on treatment strategy. *J. Surg. Oncol.* 102(6), 588–592 (2010).
55. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. *Radiology* 224(3), 748–756 (2002).
56. Glazer ES, Beatty K, Abdalla EK, Vauthey JN, Curley SA. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. *Arch. Surg.* 145(4), 340–345 (2010).
57. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. *Cancer* 47(1), 207–214 (1981).
58. Therasse P, Arbuuck SG, Eisenhauer EA *et al*. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J. Nat. Cancer Inst.* 92(3), 205–216 (2009).
59. Eisenhauer EA, Therasse P, Bogaerts J *et al*. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur. J. Cancer* 45(2), 228–247 (2009).
60. Zacharias AJ, Jayakrishnan TT, Rajeev R *et al*. Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases: a meta-analysis. *PLoS ONE* 10(10), e0139940 (2015).
61. Wang YJ, De Baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. *Chin. J. Cancer Res.* 27(2), 96–121 (2015).

62. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin. Liver Dis.* 30(1), 52–60 (2010).
63. Gillmore R, Stuart S, Kirkwood A *et al.* EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. *J. Hepatol.* 55(6), 1309–1316 (2011).
64. Lewis AL, Holden RR, Chung ST *et al.* Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model. *J. Mater. Sci. Mater. Med.* 24(1), 115–127 (2013).
65. Martin RC, 2nd, Scoggins CR, Tomalty D *et al.* Irinotecan drug-eluting beads in the treatment of chemo-naïve unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and Phase I trial. *J. Gastrointest. Surg.* 16(8), 1531–1538 (2012).
66. Pernot S, Artru P, Mithieux F *et al.* Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: a case report from the FFCD 1201 trial. *Clinics Res. Hepatol. Gastroenterol.* 39(6), e73–e77 (2015).
67. Kekez D, Badzek S, Prejac J *et al.* Fluorouracil, leucovorin and irinotecan combined with intra-arterial hepatic infusion of drug-eluting beads preloaded with irinotecan in unresectable colorectal liver metastases: side effects and results of a concomitant treatment schedule. Clinical investigation. *Tumori* 100(5), 499–503 (2014).
68. Di Noia V, Basso M, Marsico V *et al.* DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. *Future Oncol.* 15(20), 2349–2360 (2017).
69. Akinwande O, Miller A, Hayes D, O'Hara R, Tomalty D, Martin RC. Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. *Anticancer Res.* 34(12), 7239–7245 (2014).
70. Huppert P, Wenzel T, Wietholtz H. Transcatheter arterial chemo-embolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage patient population. *Cardiovasc. Interventional Radiol.* 37(1), 154–164 (2014).
71. Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. *Anticancer Res.* 33(5), 2077–2083 (2013).
72. Vogl TJ, Lahrso M, Albrecht MH *et al.* Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation. *Eur. J. Radiol.* 102, 138–145 (2018).